NEW YORK STEM CELL SUMMIT: 2014 PREVIEW (Orthopedics This Week)
Sales of stem cell products in 2013 skyrocketed, we estimate, 42% from 2012 to reach $236 million. With several new players entering the market, notably DePuy Synthes (the largest orthopedic company in the world), stem cell sales will accelerate, we estimate, by 61% to reach an eventual sales amount of $380 million. The principal driver of these sales will be improved versions of the cancellous bone with endogenous mesenchymal stem cells (MSCs), new allograft liquid forms with endogenous MSCs for orthopedic use and sharply rising visibility of cell-based companies and recent clinical study results.
The value of the 47 stem cell companies we track rose 82% in 2013 and at the start of 2014 stood at an aggregate $7.6 billion.
The companies and people who are behind this remarkable story of innovation and sales growth will be on the podium at the 9th Annual New York Stem Cell Summit on February 18. For registration information click here.
Here is a preview of what we expect will be the highlights of this year’s Summit.
Allograft Bone With Endogenous Mesenchymal Stem Cells
Stem cell business models are difficult to design b...
